[Skip to Content]
[Skip to Content Landing]
May 2013

Successful Treatment With Vemurafenib in BRAF V600K–Positive Cerebral Melanoma Metastasis

Author Affiliations

Author Affiliations: Departments of Dermatology (Drs Forschner, Bauer, Garbe, and Meier and Ms Niessner) and Neuroradiology (Dr Bender), Eberhard-Karls University of Tuebingen, Tuebingen, Germany.

JAMA Dermatol. 2013;149(5):642-644. doi:10.1001/jamadermatol.2013.372

More than 90% of the BRAF mutations in melanoma are identified at codon 600, and about 80% of these are BRAF V600E mutations. The second most common mutation is the BRAF V600K mutation, representing 14% to 28% of BRAF mutations in melanoma.1 Vemurafenib treatment for metastatic melanoma has been extensively studied in patients harboring the BRAF V600E mutation. There are rare data concerning the BRAF V600K mutation.

First Page Preview View Large
First page PDF preview
First page PDF preview